Literature DB >> 25188809

Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.

Saloua Tagmouti1, Madeline Slater, Andrea Benedetti, Sandra V Kik, Niaz Banaei, Adithya Cattamanchi, John Metcalfe, David Dowdy, Richard van Zyl Smit, Nandini Dendukuri, Madhukar Pai, Claudia Denkinger.   

Abstract

RATIONALE: Interferon gamma (IFN-γ) release assays for latent tuberculosis infection result in a larger-than-expected number of conversions and reversions in occupational screening programs, and reproducibility of test results is a concern.
OBJECTIVES: Knowledge of the relative contribution and extent of the individual sources of variability (immunological, preanalytical, or analytical) could help optimize testing protocols.
METHODS: We performed a systematic review of studies published by October 2013 on all potential sources of variability of commercial IFN-γ release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB). The included studies assessed test variability under identical conditions and under different conditions (the latter both overall and stratified by individual sources of variability). Linear mixed effects models were used to estimate within-subject SD.
MEASUREMENTS AND MAIN RESULTS: We identified a total of 26 articles, including 7 studies analyzing variability under the same conditions, 10 studies analyzing variability with repeat testing over time under different conditions, and 19 studies reporting individual sources of variability. Most data were on QuantiFERON (only three studies on T-SPOT.TB). A considerable number of conversions and reversions were seen around the manufacturer-recommended cut-point. The estimated range of variability of IFN-γ response in QuantiFERON under identical conditions was ±0.47 IU/ml (coefficient of variation, 13%) and ±0.26 IU/ml (30%) for individuals with an initial IFN-γ response in the borderline range (0.25-0.80 IU/ml). The estimated range of variability in noncontrolled settings was substantially larger (±1.4 IU/ml; 60%). Blood volume inoculated into QuantiFERON tubes and preanalytic delay were identified as key sources of variability.
CONCLUSIONS: This systematic review shows substantial variability with repeat IFN-γ release assays testing even under identical conditions, suggesting that reversions and conversions around the existing cut-point should be interpreted with caution.

Entities:  

Keywords:  IFN-γ release assays; diagnostics; reproducibility; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 25188809      PMCID: PMC5469356          DOI: 10.1513/AnnalsATS.201405-188OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  41 in total

1.  Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay.

Authors:  Victor Herrera; Ellen Yeh; Kelly Murphy; Julie Parsonnet; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection.

Authors:  David Doberne; Rajiv L Gaur; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

3.  Performance of QuantiFERON-TB Gold and tuberculin skin test relative to subjects' risk of exposure to tuberculosis.

Authors:  Sharon E McMullen; David A Pegues; Frances S Shofer; Alexandra C Sheller; Evelyn B Wiener
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

4.  IFN-γ release assay conversions and reversions. Challenges with serial testing in U.S. health care workers.

Authors:  Manish Joshi; Thomas P Monson; Anita Joshi; Gail L Woods
Journal:  Ann Am Thorac Soc       Date:  2014-03

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Systematic reviews of diagnostic test accuracy.

Authors:  Mariska M G Leeflang; Jonathan J Deeks; Constantine Gatsonis; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2008-12-16       Impact factor: 25.391

7.  Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB gold in-tube assay.

Authors:  Rajiv L Gaur; Madhukar Pai; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

8.  Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube tests.

Authors:  William C Whitworth; Lanette R Hamilton; Donald J Goodwin; Carlos Barrera; Kevin B West; Laura Racster; Laura J Daniels; Stella O Chuke; Brandon H Campbell; Jamaria Bohanon; Atheer T Jaffar; Wanzer Drane; David Maserang; Gerald H Mazurek
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

9.  Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests.

Authors:  Richard D Powell; William C Whitworth; John Bernardo; Patrick K Moonan; Gerald H Mazurek
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

10.  Variability of the QuantiFERON®-TB gold in-tube test using automated and manual methods.

Authors:  William C Whitworth; Donald J Goodwin; Laura Racster; Kevin B West; Stella O Chuke; Laura J Daniels; Brandon H Campbell; Jamaria Bohanon; Atheer T Jaffar; Wanzer Drane; Paul A Sjoberg; Gerald H Mazurek
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more
  38 in total

1.  Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?

Authors:  M G Johnson; R W Bialas; R P Hall; J E Stout
Journal:  J Dermatolog Treat       Date:  2015-12-10       Impact factor: 3.359

2.  Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Authors:  Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

3.  Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection.

Authors:  Thara K Venkatappa; Rose Punnoose; Dolly J Katz; Michael P Higgins; Niaz Banaei; Edward A Graviss; Robert W Belknap; Christine S Ho
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

4.  Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers.

Authors:  Oh Joo Kweon; Yong Kwan Lim; Hye Ryoun Kim; Tae-Hyoung Kim; Mi-Kyung Lee
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

Review 5.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

Review 6.  Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?

Authors:  Niaz Banaei; Rajiv L Gaur; Madhukar Pai
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

7.  Quantitative IFN-γ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study.

Authors:  Rishi K Gupta; Marc Lipman; Charlotte Jackson; Alice J Sitch; Jo Southern; Francis Drobniewski; Jonathan J Deeks; Chuen-Yan Tsou; Chris Griffiths; Jennifer Davidson; Colin Campbell; Oliver Stirrup; Mahdad Noursadeghi; Heinke Kunst; Pranab Haldar; Ajit Lalvani; Ibrahim Abubakar
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

8.  Performance of Interferon-Gamma and IP-10 Release Assays for Diagnosing Latent Tuberculosis Infections in Patients with Concurrent Malaria in Tanzania.

Authors:  Camilla H Drabe; Lasse S Vestergaard; Marie Helleberg; Nyagonde Nyagonde; Michala V Rose; Filbert Francis; Ola P Theilgaard; Jens Asbjørn; Ben Amos; Ib Christian Bygbjerg; Morten Ruhwald; Pernille Ravn
Journal:  Am J Trop Med Hyg       Date:  2016-02-01       Impact factor: 2.345

9.  Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT.(®)TB and QFT-GIT).

Authors:  Richard N van Zyl-Smit; Rannakoe J Lehloenya; Richard Meldau; Keertan Dheda
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

10.  Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Assunta Navarra; Valentina Vanini; Gilda Cuzzi; Claudia Cimaglia; Luigi Ruffo Codecasa; Carmela Pinnetti; Niccolò Riccardi; Fabrizio Palmieri; Andrea Antinori; Delia Goletti
Journal:  J Infect       Date:  2020-02-22       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.